Neurodegenerative Disease Therapeutics Market to Reach USD 93.17 Billion by 2034 at 6.32% CAGR | DelveInsight

DelveInsight's "Neurodegenerative Disease Therapeutics Market Insights, Size, and Forecast 2034" report delivers an in-depth understanding of the neurodegenerative disease therapeutics market trends, growth drivers, restraints, competitive landscape, and regional dynamics across North America, Europe, Asia-Pacific, and the Rest of the World.

Explore the intricate details of the Neurodegenerative Disease Therapeutics Market Report @ https://www.delveinsight.com/report-store/neurodegenerative-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from Neurodegenerative Disease Therapeutics Market Report
• In December 2025, Mitsubishi Tanabe Pharma Corporation entered into an agreement with Shionogi & Co., Ltd. for the sale of global rights to its RADICAVA ORS and IV RADICAVA (edaravone) ALS franchise for approximately USD 2.5 billion.
• The global neurodegenerative disease therapeutics market is estimated at USD 53.94 billion in 2025 and is projected to reach USD 93.17 billion by 2034, expanding at a CAGR of 6.32% during 2026-2034.
• By drug modality, small molecules dominated the market with a 55% share in 2025.
• By drug class, cholinesterase inhibitors accounted for the largest market share at 28% in 2025.
• By route of administration, oral held the leading position with a 62% market share in 2025.
• By disease type, Alzheimer's disease dominated the market with a 43% share in 2025.
• By end-users, hospitals accounted for the largest share at 57% in 2025.
• North America held the largest regional market share at 42% in 2025, while Asia-Pacific is projected to experience the fastest growth through 2034.
• Key Neurodegenerative Disease Therapeutics Companies include Biogen Inc., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Novartis AG, AbbVie Inc., Amneal Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma Corporation, PTC Therapeutics, Inc., H. Lundbeck A/S, and others.

Get a Free sample for the Neurodegenerative Disease Therapeutics Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/neurodegenerative-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

What is Neurodegenerative Disease Therapeutics?
Neurodegenerative disease therapeutics comprise the pharmaceutical and biologic products used to treat progressive disorders characterized by the gradual degeneration and loss of neuronal structure and function within the central nervous system, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). Because these conditions are chronic, largely irreversible, and driven by distinct underlying pathologies such as amyloid-beta and tau accumulation, alpha-synuclein aggregation, and motor neuron degeneration, treatment approaches span symptomatic small-molecule therapies, disease-modifying monoclonal antibodies, and emerging gene and cell therapy platforms.

Neurodegenerative Disease Therapeutics Market Segmentation
Drug Modality: Small Molecules, Monoclonal Antibodies, Gene Therapies, Cell Therapies, Others Drug Class: Anti-Amyloid Therapies, Cholinesterase Inhibitors, Anti-Tau Therapies, NMDA Receptor Antagonists, Others Route of Administration: Oral, Intravenous (IV), Subcutaneous, Others Disease Type: Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis (ALS), Others End-Users: Hospitals, Neurologic Clinics, Others Geography: North America, Europe, Asia-Pacific, Rest of the World

Download the report to understand which factors are driving neurodegenerative disease therapeutics market trends @ https://www.delveinsight.com/report-store/neurodegenerative-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Neurodegenerative Disease Therapeutics Market Key Growth Drivers
• Rising global prevalence of neurodegenerative disorders, with the World Health Organization reporting approximately 57 million people living with dementia worldwide in 2025 and the Parkinson's Foundation estimating more than 10 million people living with Parkinson's disease globally.
• Advancements in disease-modifying therapies, anchored by the FDA approval of Leqembi in January 2023 and Kisunla in July 2024, both targeting amyloid-beta pathology in early Alzheimer's disease.
• The expanding pipeline of RNA-based, gene, and cell therapies, exemplified by the FDA approval of Qalsody in April 2023 for SOD1-linked ALS.
• Increasing investment in neuroscience research and drug development by pharmaceutical companies, biotechnology firms, governments, and research institutions.
• Accelerating regulatory approvals and label expansions, including the April 2025 European Commission approval of Leqembi as the first disease-modifying Alzheimer's therapy authorized in Europe.
• Growing collaboration between large pharmaceutical companies and specialized biotechnology firms, such as the Novartis and PTC Therapeutics partnership on votoplam for Huntington's disease.
• Strong pharmaceutical and investor interest in neuroscience, highlighted by Shionogi's December 2025 agreement to acquire global rights to Mitsubishi Tanabe Pharma's RADICAVA franchise for approximately USD 2.5 billion.

Neurodegenerative Disease Therapeutics Market Restraints
The market faces restraints including high failure rates in clinical trials, as many drug candidates fail during late-stage development due to inadequate efficacy or safety concerns in complex central nervous system disorders, exemplified by the FDA's August 2025 Complete Response Letter for PTC Therapeutics' vatiquinone in Friedreich's ataxia. The blood-brain barrier continues to restrict the penetration of large-molecule biologics and many small-molecule candidates into the brain, limiting therapeutic effectiveness. High treatment costs and uneven reimbursement for newer amyloid- and tau-targeting therapies limit adoption in price-sensitive markets, while the need for specialized diagnostic infrastructure, including amyloid PET imaging and biomarker testing, adds further complexity to patient identification and treatment initiation. Safety monitoring requirements associated with amyloid-related imaging abnormalities (ARIA) for monoclonal antibody therapies add cost and complexity to treatment administration, and a shortage of specialized neurologists in emerging markets constrains broader adoption.

Neurodegenerative Disease Therapeutics Companies
Biogen Inc., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Novartis AG, AbbVie Inc., Amneal Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma Corporation, PTC Therapeutics, Inc., H. Lundbeck A/S, and others.

Discover more about companies set to grab major Neurodegenerative Disease Therapeutics market share @ https://www.delveinsight.com/sample-request/neurodegenerative-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Neurodegenerative Disease Therapeutics Market Outlook
North America led the market with a 42% share in 2025, supported by advanced healthcare infrastructure, high disease prevalence, and rapid adoption of innovative therapies, particularly in the United States, which has been at the forefront of disease-modifying therapy approvals including Leqembi and Kisunla. Asia-Pacific is projected to be the fastest-growing region through 2034, driven by a rapidly aging population, rising burden of neurological disorders, and improving access to advanced healthcare services across China, Japan, India, and South Korea. Europe remains a large and advanced market, supported by established European Medicines Agency regulatory frameworks and continued neuroscience R&D investment by companies including Roche and Novartis. The Rest of World region, spanning Latin America, the Middle East, and Africa, represents an emerging growth frontier as neurological care infrastructure and treatment access expand. The market is classified as Moderately Concentrated, with large diversified pharmaceutical companies including Biogen, Eisai, Eli Lilly, and Roche anchoring the top tier alongside specialized companies such as Amneal Pharmaceuticals, Mitsubishi Tanabe Pharma, PTC Therapeutics, and H. Lundbeck.

Scope of the Neurodegenerative Disease Therapeutics Market Report
• Study Period: 2023-2034
• Forecast Period: 2026-2034
• Coverage: North America, Europe, Asia-Pacific, and Rest of the World
• Neurodegenerative Disease Therapeutics Companies: Biogen Inc., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Novartis AG, AbbVie Inc., Amneal Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma Corporation, PTC Therapeutics, Inc., H. Lundbeck A/S, and others
• Neurodegenerative Disease Therapeutics Market Segmentation: By Drug Modality, Drug Class, Route of Administration, Disease Type, End-Users, and Geography
• Neurodegenerative Disease Therapeutics Market Dynamics: Market drivers and market restraints
• Competitive Landscape Analysis: Market concentration, leading players, geographic reach, pipeline strength, regulatory track record, strategic partnerships, M&A activity, manufacturing and commercial capabilities, and innovation focus

To know more about neurodegenerative disease therapeutics companies working in the market, visit @ https://www.delveinsight.com/sample-request/neurodegenerative-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Contents
1. Neurodegenerative Disease Therapeutics Market Report Introduction
2. Neurodegenerative Disease Therapeutics Market Executive Summary
3. Neurodegenerative Disease Therapeutics Market Key Factors Analysis
4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
5. Regulatory Analysis
6. Neurodegenerative Disease Therapeutics Market Porter's Five Forces Analysis
7. Neurodegenerative Disease Therapeutics Market Assessment
8. Neurodegenerative Disease Therapeutics Market Competitive Landscape
9. Neurodegenerative Disease Therapeutics Market Startup Funding and Investment Trends
10. Neurodegenerative Disease Therapeutics Market Company and Product Profiles
11. Neurodegenerative Disease Therapeutics Report KOL Views
12. Project Approach
13. About DelveInsight
14. Disclaimer and Contact Us

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.